In February 2019, the Company implemented corporate changes to focus its resources on advancing its clinical-stage therapeutic candidates. As a result, the Company is concentrating on completing the SER-287 Phase 2b study in mild-to-moderate UC, obtaining results from the ongoing SER-109 Phase 3 study for recurrent CDI, advancing the SER-401 Phase 1b study, in collaboration with the Parker Institute for Cancer Immunotherapy and MD Anderson Cancer Center, to evaluate augmenting checkpoint inhibitor response in patients with metastatic melanoma and advancing SER-301 into clinical development. In connection with the prioritization of these therapeutic candidates, the Company made changes to its management team and reduced headcount by approximately 30 percent.

During the nine months ended September 30, 2019 the Company recorded charges of $1,492, related to severance and other termination benefits. No restructuring charges were recorded during the three months ended September 30, 2019.During the three and nine months ended September 30, 2019 the Company paid $206 and $1,101, respectively, and it expects to pay approximately $391 in the remainder of 2019.

The outstanding restructuring liabilities are included in accrued expenses and other current liabilities on the condensed consolidated balance sheets. As of September 30, 2019, the components of the liabilities were as follows:

	Employee Severance and Other Benefits
Restructuring expenses	$	1,492
Cash payments	$	(1,101	)
Liability included in accrued expenses and other current liabilities at September 30, 2019	$	391